BioSpace News Archive

Quantzig, a global data analytics and advisory firm, that delivers actionable analytics solutions to resolve complex business problems brings to you a comprehensive portfolio of analytics solutions tailored to meet the real world needs of pharma and life sciences companies.

People infected with COVID-19 diagnosed in the last 24 hours can call 1-877-536-6837 to participate in clinical research aimed to stop the progression of the disease.

Policy Reporter, a TrialCard-owned medical policy tracking platform for physicians, health plans, laboratories, and product manufacturers, has over the past week alerted its clients to dozens of new and updated payer policies related to the COVID-19 virus

Jumptuit Health, Inc. announced today the establishment of a Task Force to implement a National Individualized Health Alert System (NIHAS) for COVID-19 and other infectious diseases.

Honor From MTF Biologics and AOPO Recognizes Organ Procurement Organization Serving Western Pennsylvania and West Virginia for Its Exemplary Support of Donor Families

Pfizer Inc. (NYSE: PFE) today announced the completion of a $1.25 billion ten-year “sustainability” bond paying interest semi-annually of 2.625 percent and maturing April 1, 2030.

New York-based Aquavit Pharmaceuticals, Inc. (Aquavit), a biotechnology company focused on the development of a first-of-its-kind microchannel drug delivery technology, today announces that the company has filed two patent applications with the United States Patent and Trademark Office.

EPAM Systems, Inc. (NYSE: EPAM), a leading global provider of digital platform engineering and software development services, today announced that it has released the GENTL Mask, an open source solution for manufacturers to address the supply shortage of protective masks that medical professionals need amid the coronavirus outbreak

Rising Pharma Holdings Inc., the global pharmaceutical company operating as Rising Pharmaceuticals, today announced its collaborative agreement with the Division of Infectious Disease and International Medicine at the University of Minnesota, Department of Infectious Disease on a clinical trial exploring hydroxychloroquine as preventive treatment for coronavirus disease 2019 (COVID-19)

Bristol Myers Squibb (NYSE:BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion for ZEPOSIA® (ozanimod) for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease as defined by clinical or imaging features. ZEPOSIA is an oral, sphingosine 1-phosphate (S1P) receptor modulator that binds with high affinity selectively to S1P subtypes 1 (S1P1) and 5 (S1P5).